Want to see FR:BIM full AI Analyst Report?
BIM Stock Chart & Stats
€91.25
€1.20(1.14%)
At close: 4:00 PM EST
€91.25
€1.20(1.14%)
Day’s Range― - ―
52-Week Range€65.60 - €128.30
Previous CloseN/A
Volume6.19K
Average Volume (3M)107.98K
Market Cap
€8.41B
Enterprise Value€7.89B
Total Cash (Recent Filing)€569.80M
Total Debt (Recent Filing)€461.40M
Price to Earnings (P/E)20.7
Beta0.68
Next Earnings
Jul 28, 2026EPS Estimate
2.14Next Dividend Ex-DateN/A
Dividend Yield0.82%
Share Statistics
EPS (TTM)3.37
Shares Outstanding118,361,220
10 Day Avg. Volume122,242
30 Day Avg. Volume107,982
Financial Highlights & Ratios
PEG Ratio-4.00
Price to Book (P/B)3.17
Price to Sales (P/S)3.20
P/FCF Ratio28.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€76.70Price Target Upside-15.95% Downside
Rating ConsensusHold
Number of Analyst Covering8
EPS Forecast (FY)4.42
Revenue Forecast (FY)€4.12B
Bulls Say, Bears Say
Bulls Say
Guidance IncreaseFull-year guidance was uplifted from 6-8% to 8-10% organic sales growth.
Organic GrowthOrganic growth for the quarter was 10.3%, surpassing the consensus expectation of 8.4%.
Product LaunchesNew product launches like SPOTFIRE, VITEK, and VIDAS approvals are driving in-market traction.
Bears Say
Installed Base GrowthBIOFIRE installed base growth slowdown may be debated.
Product Segment PerformanceImmunoassays are still weighed down by the decrease in procalcitonin tests.
bioMerieux News
BIM FAQ
What was bioMerieux’s price range in the past 12 months?
bioMerieux lowest stock price was €65.60 and its highest was €128.30 in the past 12 months.
What is bioMerieux’s market cap?
bioMerieux’s market cap is €8.41B.
When is bioMerieux’s upcoming earnings report date?
bioMerieux’s upcoming earnings report date is Jul 28, 2026 which is in 28 days.
How were bioMerieux’s earnings last quarter?
bioMerieux released its earnings results on Feb 27, 2026. The company reported €2.004 earnings per share for the quarter, missing the consensus estimate of €2.13 by -€0.126.
Is bioMerieux overvalued?
According to Wall Street analysts bioMerieux’s price is currently Overvalued.
Does bioMerieux pay dividends?
bioMerieux pays a Annually dividend of €0.98 which represents an annual dividend yield of 0.82%. See more information on bioMerieux dividends here
What is bioMerieux’s EPS estimate?
bioMerieux’s EPS estimate is 2.14.
How many shares outstanding does bioMerieux have?
bioMerieux has 118,361,220 shares outstanding.
What happened to bioMerieux’s price movement after its last earnings report?
bioMerieux reported an EPS of €2.004 in its last earnings report, missing expectations of €2.13. Following the earnings report the stock price went up 3.734%.
Which hedge fund is a major shareholder of bioMerieux?
Currently, no hedge funds are holding shares in FR:BIM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
bioMerieux
bioMérieux S.A. is a global entity operating across the Americas, Europe, the Middle East, Africa, and the Asia Pacific, specializing in the development and production of in vitro diagnostic solutions. The company's sophisticated systems utilize biological samples to identify infectious diseases, cardiovascular conditions, and various forms of cancer. Additionally, bioMérieux provides essential microbiological testing services for the manufacturing sectors, primarily serving the food, pharmaceutical, cosmetics, and veterinary industries. Its client base includes clinical and hospital laboratories, medical practitioners, blood banks, and industrial quality control facilities. Founded in 1963, originally under the name B-D Mérieux, bioMérieux S.A. maintains its headquarters in Marcy l'Etoile, France, and functions as a subsidiary of Institut Mérieux SA.
BIM Stock 12 Month Forecast
Average Price Target
€76.70
▼(-15.95% Downside)
Technical Analysis
Eurofins Scientific
―
Sartorius Stedim Biotech
―
Virbac SA
―
Eurofins-Cerep SA
―
Biosynex SA
―
Options Prices
Currently, No data available
---




